摘要
目的 探讨沐舒坦 (mucosolvan)治疗新生儿呼吸窘迫综合征 (NRDS)的有效性。方法 采用沐舒坦 15mg·kg-1·d-1,6h 1次静脉滴注治疗NRDS患儿 2 4例 ,并与同期未用沐舒坦治疗的 2 4例NRDS患儿进行前瞻性临床对照研究。通过血气指标及转归进行比较 ,分析判断疗效。结果 治疗组在应用沐舒坦 2 4h后氧分压 (PaO2 )由 (4 8± 12 )mmHg升高至 (5 8± 12 )mmHg ;4 8hX线片分值由 2 5± 0 98降至 1 2± 1 1,与治疗前及对照组相比均有显著性差异。治疗组机械通气及氧疗时间较对照组明显缩短。治愈率两组分别为 70 8%及 6 2 5 % ,二者差异无显著性。结论 沐舒坦不能改善NRDS的最终预后 ,能改善NRDS患儿肺顺应性及氧合功能 ,缩短机械通气、氧疗及住院时间 ,可降低治疗费用。
Objective To study the efficacy and clinical value of mucosolvan therapy in newborn infants with neonatal respiratory distress syndrome(NRDS).Methods The study was a prospective controlled clinical trial.Twenty-four neonates with NRDS were treated with mucosolvan injection(15 mg·kg 1·d 1,ivgtt,qid×7 d)and twenty-four other newborn infants with NRDS who received no mucosolvan therapy were enrolled as control group from February 2000 to December 2002.Results Before treatment and 24 hours after the mucosolvan treatment,there was significant difference in blood gas indexes,PaO 2 increased from(48±12) mmHg to (58±12) mmHg.In mucosolvan therapy group,chest X-ray films were improved obviously at 48 hours and X-ray grade descended from 2.5±0.98 to 2.1±1.1. Mechanical ventilation time and oxygen therapy time were obviously cut down in mucosolvan group than in control group.There was no significant difference in cure rate between mucosolvan group(70.8%)and control group(62.5%).Conclusion Mucosolvan can not improve the prognosis of NRDS,but it can improve the lung compliance and oxygenation function of NRDS, shorten the mechanical ventilation,oxygen therapy and hospitalization time, and decrease therapeutic cost.
出处
《中国急救医学》
CAS
CSCD
北大核心
2004年第2期105-106,共2页
Chinese Journal of Critical Care Medicine
关键词
沐舒坦
新生儿
呼吸窘迫综合征
前瞻性研究
Mucosolvan
Newborn infant
Respiratory distress syndrome
Prospective study
